Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sjögren's Systemic Clinical Activity Index (SCAI)--a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome.
Bowman SJ, Sutcliffe N, Isenberg DA, Goldblatt F, Adler M, Price E, Canavan A, Hamburger J, Richards A, Rauz S, Regan M, Gadsby K, Rigby S, Jones A, Mathew R, Mulherin D, Stevenson A, Nightingale P. Bowman SJ, et al. Among authors: rigby s. Rheumatology (Oxford). 2007 Dec;46(12):1845-51. doi: 10.1093/rheumatology/kem280. Rheumatology (Oxford). 2007. PMID: 18032543
Estimating indirect costs in primary Sjögren's syndrome.
Bowman SJ, St Pierre Y, Sutcliffe N, Isenberg DA, Goldblatt F, Price E, Hamburger J, Richards A, Rauz S, Regan M, Rigby S, Jones A, Mulherin D, Clarke AE. Bowman SJ, et al. Among authors: rigby s. J Rheumatol. 2010 May;37(5):1010-5. doi: 10.3899/jrheum.090734. Epub 2010 Apr 1. J Rheumatol. 2010. PMID: 20360188
The Sjögren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome.
Barry RJ, Sutcliffe N, Isenberg DA, Price E, Goldblatt F, Adler M, Canavan A, Hamburger J, Richards A, Regan M, Gadsby K, Rigby S, Jones A, Mathew R, Mulherin D, Stevenson A, Nightingale P, Rauz S, Bowman SJ. Barry RJ, et al. Among authors: rigby s. Rheumatology (Oxford). 2008 Aug;47(8):1193-8. doi: 10.1093/rheumatology/ken164. Epub 2008 Jun 4. Rheumatology (Oxford). 2008. PMID: 18524804
Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis.
Cordingley L, Prajapati R, Plant D, Maskell D, Morgan C, Ali FR, Morgan AW, Wilson AG, Isaacs JD; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS); Barton A. Cordingley L, et al. Arthritis Care Res (Hoboken). 2014 Jun;66(6):861-8. doi: 10.1002/acr.22249. Arthritis Care Res (Hoboken). 2014. PMID: 24339425 Free PMC article.
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators. Jani M, et al. Arthritis Rheumatol. 2015 May;67(8):2011-9. doi: 10.1002/art.39169. Arthritis Rheumatol. 2015. PMID: 26109489 Free PMC article.
Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.
Bluett J, Ibrahim I, Plant D, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD; BRAGGSS; Barton A. Bluett J, et al. Pharmacogenomics J. 2014 Apr;14(2):171-5. doi: 10.1038/tpj.2013.26. Epub 2013 Jul 16. Pharmacogenomics J. 2014. PMID: 23856853 Free PMC article.
Osmic acid revisited: factors that predict a favourable response.
Bessant R, Steuer A, Rigby S, Gumpel M. Bessant R, et al. Among authors: rigby s. Rheumatology (Oxford). 2003 Sep;42(9):1036-43. doi: 10.1093/rheumatology/keg283. Epub 2003 May 30. Rheumatology (Oxford). 2003. PMID: 12777647
286 results